This trial is studying nivolumab in combination with blinatumomab to see how well it works compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia that has come back.
2 Primary · 2 Secondary · Reporting Duration: From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
550 Total Participants · 7 Treatment Groups
Primary Treatment: Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients · No Placebo Group · Phase 2
Age 1 - 30 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: